{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:47:16Z","timestamp":1793213236375,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00520-024-08462-x","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T03:29:12Z","timestamp":1712719752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["2020 ASCO, 2023 NCCN, 2023 MASCC\/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients"],"prefix":"10.1007","volume":"32","author":[{"given":"Samantha K. F.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Goodall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shing Fung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Jocko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flay","family":"Charbonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pasetka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoo-Joung","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry C. Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Wai","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thenugaa","family":"Rajeswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Gojsevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Gralla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"8462_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0277-5379(83)90418-2","volume":"19","author":"A Coates","year":"1983","unstructured":"Coates A, Abraham S, Kaye SB et al (1983) On the receiving end\u2014patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203\u2013208","journal-title":"Eur J Cancer Clin Oncol"},{"key":"8462_CR2","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1007\/s00520-022-06804-1","volume":"30","author":"JL Vardy","year":"2022","unstructured":"Vardy JL, Liew A, Warby A et al (2022) On the receiving end: have patient perceptions of the side-effects of cancer chemotherapy changed since the twentieth century? Support Care Cancer 30:3503\u20133512","journal-title":"Support Care Cancer"},{"key":"8462_CR3","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1200\/jco.2013.31.15_suppl.6595","volume":"31","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Bouganim N, Beusterien K et al (2013) Patient perceptions about potential side effects and benefits from chemotherapy agents. J Clin Oncol 31:6595\u20136595","journal-title":"J Clin Oncol"},{"key":"8462_CR4","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s00520-018-4102-8","volume":"26","author":"M Matzka","year":"2018","unstructured":"Matzka M, K\u00f6ck-H\u00f3di S, Jahn P et al (2018) Relationship among symptom clusters, quality of life, and treatment-specific optimism in patients with cancer. Support Care Cancer 26:2685\u20132693","journal-title":"Support Care Cancer"},{"key":"8462_CR5","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1007\/s00520-010-1003-x","volume":"19","author":"SM Grunberg","year":"2011","unstructured":"Grunberg SM, Warr D, Gralla RJ et al (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity\u2014state of the art. Support Care Cancer 19:S43\u2013S47","journal-title":"Support Care Cancer"},{"key":"8462_CR6","doi-asserted-by":"publisher","first-page":"595894","DOI":"10.1155\/2015\/595894","volume":"2015","author":"RM Navari","year":"2015","unstructured":"Navari RM (2015) Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int 2015:595894\u2013595896","journal-title":"Biomed Res Int"},{"key":"8462_CR7","first-page":"e132","volume":"16","author":"RM Navari","year":"2019","unstructured":"Navari RM, Ruddy KJ, Leblanc TW et al (2019) Impact of addition of carboplatin AUC <= 4 to antiemetic guidelines for triple antiemetic prophylaxis: a gap in quality of care, guideline adoption, and avoiding acute care. Proc Am Soc Clin Oncol 16:e132\u2013e138","journal-title":"Proc Am Soc Clin Oncol"},{"key":"8462_CR8","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1007\/s00520-022-07067-6","volume":"30","author":"J Gao","year":"2022","unstructured":"Gao J, Zhao J, Jiang C et al (2022) Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study. Support Care Cancer 30:6225\u20136232","journal-title":"Support Care Cancer"},{"key":"8462_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00520-018-4464-y","volume":"27","author":"Y Razvi","year":"2019","unstructured":"Razvi Y, Chan S, McFarlane T et al (2019) ASCO, NCCN, MASCC\/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27:87\u201395","journal-title":"Support Care Cancer"},{"key":"8462_CR10","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782\u20132797","journal-title":"J Clin Oncol"},{"key":"8462_CR11","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh PJ, Kris MG, Basch E et al (2017) JOURNAL OF CLINICAL ONCOLOGY Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240\u20133261","journal-title":"J Clin Oncol"},{"key":"8462_CR12","unstructured":"Berger MJ, Agarwal R, Anand S et al\u00a0(2023) NCCN guidelines version 1.2023 antiemesis continue, \nhttps:\/\/www.nccn\n."},{"key":"8462_CR13","unstructured":"Summary of 2019 antiemetic recommendations. 2019"},{"key":"8462_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00520-016-3384-y","volume":"25","author":"LL Dupuis","year":"2017","unstructured":"Dupuis LL, Sung L, Molassiotis A et al (2017) 2016 updated MASCC\/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer 25:323\u2013331","journal-title":"Support Care Cancer"},{"issue":"32","key":"8462_CR15","first-page":"30","volume":"2023","author":"A Molassiotis","year":"2023","unstructured":"Molassiotis A, Lou AM, Fleury M et al (2023) MASCC\/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies. Support Care Cancer 2023(32):30","journal-title":"Support Care Cancer"},{"key":"8462_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00520-023-08223-2","volume":"32","author":"I Olver","year":"2024","unstructured":"Olver I, Clark-Snow R, Ruhlmann CH et al (2024) 2023 updated MASCC\/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Support Care Cancer 32:37","journal-title":"Support Care Cancer"},{"key":"8462_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00520-023-08224-1","volume":"32","author":"BL Rapoport","year":"2024","unstructured":"Rapoport BL, Herrstedt J, Snow RC et al (2024) 2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 32:36","journal-title":"Support Care Cancer"},{"key":"8462_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00520-023-08222-3","volume":"32","author":"F Scott\u00e9","year":"2024","unstructured":"Scott\u00e9 F, Schwartzberg L, Lihara H et al (2024) 2023 updated MASCC\/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Supportive Care in Cancer 32:45","journal-title":"Supportive Care in Cancer"},{"key":"8462_CR19","doi-asserted-by":"publisher","unstructured":"Herrstedt J, Celio L, Hesketh P, et al (2024) 2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Supportive Care in Cancer 32. https:\/\/doi.org\/10.1007\/s00520-023-08221-4","DOI":"10.1007\/s00520-023-08221-4"},{"key":"8462_CR20","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1007\/s00520-016-3304-1","volume":"24","author":"K Jordan","year":"2016","unstructured":"Jordan K, Gralla R, Rizzi G et al (2016) Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Support Care Cancer 24:4617\u20134625","journal-title":"Support Care Cancer"},{"key":"8462_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242\u2013249","journal-title":"Lancet Oncol"},{"key":"8462_CR22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s10147-019-01570-3","volume":"25","author":"V Vimolchalao","year":"2020","unstructured":"Vimolchalao V, Sakdejayont S, Wongchanapai P et al (2020) The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Int J Clin Oncol 25:396\u2013402","journal-title":"Int J Clin Oncol"},{"key":"8462_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134\u2013142","journal-title":"N Engl J Med"},{"key":"8462_CR24","doi-asserted-by":"publisher","unstructured":"Bajpai J, Kapu V, Rath S et al (2024) Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol.\u00a0\u00a0https:\/\/doi.org\/10.1016\/S1470-2045(23)00628-9","DOI":"10.1016\/S1470-2045(23)00628-9"},{"key":"8462_CR25","doi-asserted-by":"publisher","unstructured":"Zhao Y, Yang Y, Gao F et al (2022) A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). EClinicalMedicine 55.\u00a0https:\/\/doi.org\/10.1016\/j.eclinm.2022.101771","DOI":"10.1016\/j.eclinm.2022.101771"},{"key":"8462_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4143\/crt.2017.577","volume":"51","author":"SY Jeon","year":"2019","unstructured":"Jeon SY, Han HS, Bae WK et al (2019) A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: results of the Korean South West Oncology Group (KSWOG) study. Cancer Res Treat 51:90\u201397","journal-title":"Cancer Res Treat"},{"key":"8462_CR27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1634\/theoncologist.2014-0438","volume":"20","author":"TL Ng","year":"2015","unstructured":"Ng TL, Hutton B, Clemons M (2015) Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist 20:576\u2013583","journal-title":"Oncologist"},{"key":"8462_CR28","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00520-015-2801-y","volume":"23","author":"C Hernandez Torres","year":"2015","unstructured":"Hernandez Torres C, Mazzarello S, Ng T et al (2015) Defining optimal control of chemotherapy-induced nausea and vomiting\u2014based on patients\u2019 experience. Support Care Cancer 23:3341\u20133359","journal-title":"Support Care Cancer"},{"key":"8462_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10549-015-3669-8","volume":"155","author":"T Ng","year":"2016","unstructured":"Ng T, Mazzarello S, Wang Z et al (2016) Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. Breast Cancer Res Treat 155:337\u2013344","journal-title":"Breast Cancer Res Treat"},{"key":"8462_CR30","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.ctrv.2015.09.007","volume":"41","author":"B Hutton","year":"2015","unstructured":"Hutton B, Clemons M, Mazzarello S et al (2015) Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer\u2014an inspection of the evidence base informing clinical decision-making. Cancer Treat Rev 41:951\u2013959","journal-title":"Cancer Treat Rev"},{"key":"8462_CR31","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1186\/s12885-021-08572-3","volume":"21","author":"S Yamamoto","year":"2021","unstructured":"Yamamoto S, Iihara H, Uozumi R et al (2021) Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials. BMC Cancer 21:832","journal-title":"BMC Cancer"},{"key":"8462_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27551","volume":"66","author":"V Radhakrishnan","year":"2019","unstructured":"Radhakrishnan V, Joshi A, Ramamoorthy J et al (2019) Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: a double-blind, placebo-controlled, phase III randomized trial. Pediatr Blood Cancer 66:e27551","journal-title":"Pediatr Blood Cancer"},{"key":"8462_CR33","unstructured":"Food and Drug Administration\u00a0 (2019) Highlights of prescribing information: EMEND (fosaprepitant) for injection, for intravenous use, www.fda.gov\/medwatch"},{"key":"8462_CR34","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1002\/onco.13716","volume":"26","author":"M Aapro","year":"2021","unstructured":"Aapro M, Scott\u00e9 F, Escobar Y et al (2021) Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist 26:e1073\u2013e1082","journal-title":"Oncologist"},{"key":"8462_CR35","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","volume":"9","author":"RM Navari","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. Journal of Supportive Oncology 9:188\u2013195","journal-title":"Journal of Supportive Oncology"},{"key":"8462_CR36","doi-asserted-by":"publisher","first-page":"e27488","DOI":"10.1002\/pbc.27488","volume":"66","author":"K McKinnon","year":"2019","unstructured":"McKinnon K, Jupp J, Ghosh S et al (2019) Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals. Pediatr Blood Cancer 66:e27488","journal-title":"Pediatr Blood Cancer"},{"key":"8462_CR37","doi-asserted-by":"publisher","first-page":"e30210","DOI":"10.1002\/pbc.30210","volume":"70","author":"M Kacar","year":"2023","unstructured":"Kacar M, MacDonald P, Gibson P (2023) Addressing adherence to guidelines on prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients. Pediatr Blood Cancer 70:e30210","journal-title":"Pediatr Blood Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08462-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08462-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08462-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:11:53Z","timestamp":1715591513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08462-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["8462"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08462-x","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}